Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that was studied in the DECLARE-TIMI 58 and DAPA-CKD trials. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the lessons from the DECLARE and DAPA-CKD trials about dapagliflozin’s impact on cardiovascular and renal events.
The abstract entitled ‘Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What are the risk factors for cardiovascular and renal events in patients with type 2 diabetes? (0:21)
- What did the DECLARE and DAPA-CKD clinical trials teach us about the impact of dapagliflozin on cardiovascular and renal events? (1:53)
Disclosures: Filipe Moura has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
